Vol. 5 No. 10 (2025)
Reimbursement Reviews

Durvalumab (Imfinzi), Carboplatin, Paclitaxel

decorative image of the issue cover

Published October 15, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses durvalumab (Imfinzi) 50 mg/mL, concentrate for IV infusion.
  • Indication: Durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by durvalumab as monotherapy.